Pyoderma gangrenosum
Pyoderma gangrenosum chirwere chisingawanikwe, chinozvimba ganda apo mapustules anorwadza kana mapundu anova maronda anokura zvishoma nezvishoma. Pyoderma gangrenosum haina utachiona. Mishonga inogona kusanganisira corticosteroids, cyclosporin, kana akasiyana monoclonal antibodies. Kunyangwe zvichigona kubata vanhu vezera ripi zvaro, zvinonyanya kubata vanhu vane makore ekuma40 nema50s.
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Pagumbo remunhu ane ulcerative colitis.
References
Pyoderma gangrenosum chiitiko cheganda chisingawanzo chinokonzera maronda anorwadza ane tsvuku kana purplish edges. Inotsanangurwa sechirwere chinopisa uye chikamu cheboka rinonzi neutrophilic dermatoses. Chikonzero che pyoderma gangrenosum chakaoma, chinosanganisira matambudziko ane ese ari maviri ekuzvarwa uye anochinja ekudzivirira muvanhu vane genetic prone. Munguva pfupi yapfuura, vatsvakurudzi vakatarisa kune bvudzi rebvudzi sechinhu chinogona kutanga chirwere.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum chiitiko cheganda chisingawanzo kukonzeresa maronda anorwadza zvakanyanya. Kunyange isu tisinganzwisise zvizere chikonzero chayo, tinoziva kuti inosanganisira kuwedzera kwekuita kwemamwe maseru ekudzivirira. Kurapa chirwere ichi hakusi nyore. Tine mishonga yakasiyana-siyana inodzvanyirira immune system kana kugadzirisa basa rayo. Padivi peizvi, tinotarisawo pakurapa maronda uye kugadzirisa marwadzo. Corticosteroids uye cyclosporine inowanzova sarudzo yekutanga yekurapa, asi nguva pfupi yadarika, kwave netsvakiridzo yakawanda pakushandisa mishonga yebiologic seTNF-α inhibitors. Aya ma biologics ari kuwedzera kufarirwa, kunyanya muvarwere vane mamwe mamiriro ekuzvimba, uye ari kushandiswa kare mukuita kwechirwere.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
